| Date | Title | Description |
| 02.09.2026 | С первого дубля | С первого дубля Иностранные инновации в фармацевтике появятся в стране через российские копии
С марта 2026 года Минздрав одобрил клинические исследования (КИ) как минимум семи инновационных разработок иностранных компаний, которые только не... |
| 28.08.2026 | CNBC Daily Open: Tariffs in spotlight — and Trump has a new name for a lake | President Donald Trump’s administration is reportedly mulling over new tariffs on semiconductors used in the U.S.
Tech giant Nvidia is increasing support for Chinese artificial intelligence models as it warns of a crackdown by the U.S.
Sout... |
| 27.08.2026 | FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients | The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens.
The tablet combines bictegrav... |
| 20.08.2026 | Bevy Smith and Patrik-Ian Polk to Host 'Muses, Co-Conspirators & Champions' During Atlanta Black Pride | iN-Hale and Gilead Logos
Produced by iN-Hale Media & Entertainment and powered by Gilead Sciences, the immersive cultural experience celebrates Black queer culture, community & allyship
The collaboration represents a meaningful inve... |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования
«Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 13.08.2026 | Khartis Therapeutics Raises $50M To Advance Oral Immunology Drugs | Khartis Therapeutics Raises $50M Series B
Khartis Therapeutics has raised $50 million in Series B funding to advance its oral medicine pipeline.mForge Life Science Partners led the round. Longwood Fund and Alexandria Venture Investments joi... |
| 29.07.2026 | HIV Prevention Shot Posts Zero Infections in Extended Trial: Access Crisis Grows | By Alfredo Hanson
Published: Jul 29 2026, 11:16 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 03.07.2026 | Bundibugyo Ebola Finally Has a Diagnostic: WHO Lists First Test After 438 Deaths | By Chase Fiorini
Published: Jul 03 2026, 3:09 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 29.06.2026 | Ebola Outbreak at 1,176 Cases: First Drug Trial for Bundibugyo Strain Launches This Week | By John Bright
Published: Jun 29 2026, 11:59 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 29.06.2026 | Andera Partners joins the European Life Sciences Coalition (ELSC) with the aim to support the mobilization of capital for life sciences innovation in Europe. | Andera Partners joins the European Life Sciences Coalition (ELSC), alongside Forbion, HealthCap, Novo Holdings, Omega Funds, Sofinnova Partners, Van Lanschot Kempen, VIB, BioInnovation Institute, 4BIO Capital, Cooley and Covington.
Launched... |
| 16.06.2026 | Colorado receives FDA permission to import cheaper drugs — including Ozempic — from Canada | Getting your Trinity Audio player ready...
Colorado finally has federal permission to start importing cheaper prescription drugs from Canada, but the state may not have any sellers to work with.
Lawmakers passed a bill in 2019 that directed... |
| 10.06.2026 | PhoreMost announces lead oncology programme and appoints Chief Medical Officer to support clinical entry | Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1
Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secon... |
| 16.05.2026 | CU Boulder sees 11th startup reach $1 billion unicorn status | Getting your Trinity Audio player ready...
Forge Nano, an advanced materials company and University of Colorado Boulder startup, has reached a $1.6 billion valuation, making it CU Boulder’s 11th “unicorn,” or a privately held company with a... |
| 11.05.2026 | National casting call for E. Lynn Harris Invisible Life: The Musical With Original Score by Ashford & Simpson Announced | Invisible Life The Musical Casting
Invisible Life Casting Call
CASTING CALL: E. LYNN HARRIS INVISIBLE LIFE: THE MUSICAL (score Ashford & Simpson) DC Black Pride Celebration @ Howard Theater DC Sponsored by Gilead Sciences
This casting c... |
| 24.04.2026 | Four Swiss companies appoint new CEOs across tech and pharma |
Altoo, a Swiss wealth management platform that consolidates financial data across banking, investments and alternative holdings into a single digital interface, has appointed Achille Deodato as Chief Executive Officer. Deodato succeeds Ian... |
| 19.04.2026 | Gilead Sciences: Expanded PEPFAR And Global Fund Investment To Scale Lenacapavir HIV Prevention Access | Gilead Sciences announced an expanded investment from the U.S. State Department, PEPFAR, and The Global Fund to increase global access to its long-acting HIV prevention therapy, lenacapavir. The additional commitment is expected to extend a... |
| 07.04.2026 | Gilead приобретает немецкого производителя противораковых препаратов Tubulis за $5 млрд | Во вторник американская фармкомпания Gilead объявила о планах приобретения частной немецкой компании Tubulis GmbH за сумму до $5 млрд. Сделка направлена на расширение портфеля компании за счет перспективного класса экспериментальных противо... |
| 26.03.2026 | Keymed Biosciences Announces 2025 Annual Results and Business Updates | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.
Revenue Leaps... |
| 24.03.2026 | Gilead покупает Ouro Medicines более чем за $2 млрд и усиливает ставку на иммунологию | По условиям сделки Gilead выплатит инвесторам Ouro $1,68 млрд авансом наличными, а также еще до $500 млн в случае достижения определенных этапов разработки препарата. Ключевым активом в этой покупке является экспериментальный препарат OM336... |
| 17.03.2026 | Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer | Collaboration spans implementation pilots, evidence generation, and nationwide distribution of customized navigation tools for lung and breast cancer
SAN FRANCISCO, March 17, 2026 /PRNewswire-PRWeb/ -- Manta Cares, an award-winning digital ... |
| 14.03.2026 | ORO Labs Secures $100M to Revolutionize Enterprise AI Procurement | ORO Labs, an AI-driven procurement orchestration leader, secured $100 million in Series C funding. This capital injection follows a year of 300% revenue growth. The platform modernizes enterprise procurement. It streamlines complex global s... |
| 12.03.2026 | ORO Labs raises $100M to expand procurement orchestration platform
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Procurement orchestration platform company ORO Labs Inc. announced today that it has raised $100 million in new funding to accelerate its expansion, further develop its product and scale up customer success and deployment worldwide.
Founded... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 26.02.2026 | Lessons from COVID-19: How Agile Governance is Transforming Pharmaceutical Launch Readiness | George Stephen, Pharmaceutical Executive at Gilead Sciences
The COVID-19 pandemic forced the pharmaceutical industry to do what once seemed impossible: compress launch cycles that traditionally stretched over a decade into mere months.
The ... |
| 26.02.2026 | Novartis, Genentech file suit alleging illegal importation of prescription drug | Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
The importation of the drug, which has strict shipping and temperature controls, potentially puts ... |
| 25.02.2026 | 2026 CNBC Changemakers: Women leaders who defied the odds to reach the highest levels of success | The 2026 CNBC Changemakers list ranges from startup founders to high-profile stars such as Kim Kardashian and Selena Gomez, women leading in the AI industry, and those transforming the fields of sports and entertainment.
All of the Changema... |
| 24.02.2026 | Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy | - |
| 23.02.2026 | Maazah Raises $2M in Seed Funding | Maazah, a Minneapolis, MN-based based food brand developing dips and sauces, raised $2M Seed funding.
Backers were not disclosed.
The company intends to use the funds to support nationwide retail growth and expanded distribution.
Founded by... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 23.02.2026 | Gilead Sciences Acquires Arcellx, for $7.8 Billion | Gilead Sciences, Inc. (Nasdaq: GILD), a Foster City, California-based provider of biopharmaceutical medicines for life-threatening diseases, acquired Arcellxi (NASDAQ:ACLX) , a Redwood City, California-based provider of innovative immunothe... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 17.02.2026 | Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity | Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers—Delivering Risk Prediction Where Proteomics Falls Short
MORRISVILLE, N.C., Feb. 17, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomic... |
| 11.02.2026 | Eli Lilly Secures Future with Orna Therapeutics Acquisition | Eli Lilly acquired Orna Therapeutics. The deal totals up to $2.4 billion. This secures groundbreaking circular RNA technology. Orna pioneers *in vivo* cell engineering. Their platform allows the body to generate therapies internally. This b... |
| 09.02.2026 | Фармкомпания Eli Lilly покупает американскую биотех-компанию Orna Therapeutics за $2,4 млрд | Американская фармацевтическая компания Eli Lilly (LLY.N) согласилась купить биотехнологическую компанию Orna Therapeutics за $2,4 млрд наличными, получив доступ к технологии, которая позволяет использовать собственные клетки пациентов для с... |
| 29.01.2026 | Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" | HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-dep... |
| 18.01.2026 | I talked to many health CEOs out West and see big things for drug stocks | - |
| 15.01.2026 | To knock down health-system hurdles between you and HIV prevention, try these 6 things | Getting your Trinity Audio player ready...
By Zach Dyer, Oona Zenda, KFF Health News
When Matthew Hurley was looking to take PrEP to prevent HIV, the doctor hadn’t heard of the medicine, and when he finally did prescribe PrEP, the bills sen... |
| 08.01.2026 | Patient advocacy groups urge U.S. court to halt overseas prescription drug operations | Patient advocates are asking a federal appeals court to crack down on third-party vendors that obtain prescription drugs from overseas for U.S. patients, arguing the practice exposes them to unsafe supply chains and undermines U.S. drug saf... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 16.12.2025 | Great Point Partners Acquires Majority Stake In Lenis Group And Names Michel Vounatsos As Chairman | Great Point Partners, a Greenwich-based healthcare-focused private investment firm, has acquired a majority stake in Lenis Group, a Slovenia-based commercialization and distribution partner for niche and specialty prescription medicines acr... |
| 08.11.2025 | Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein Therapies | Accipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo... |
| 07.11.2025 | Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein Therapies | Accipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish... |
| 05.11.2025 | Global medical firms showcase innovations at CIIE | The Pascal precision transcatheter valve repair system is showcased at the booth of Edwards Lifesciences, a US-based structural heart innovation company, during the 8th CIIE held in Shanghai. [Photo provided to chinadaily.com.cn]
The 8th Ch... |
| 04.11.2025 | From Excel to Intelligence: Why Clinical Supply Planning Needs an SAP IBP Governance Layer | Share
Share
Share
Share
Email
In clinical operations, precision is non-negotiable. Yet, the systems designed to forecast, plan and distribute trial materials often depend on spreadsheets stitched together by anxious planners racing against ... |
| 03.11.2025 | The Billion-Dollar Biology of Oncology: What Really Drives Pharma’s Appetite? | By Jonathan Tobin, Partner – Brandon Capital
Plenty is written about the trends in dollars and modalities being invested in oncology by VCs. But equally important are the exits, and for early-stage investors M&A is especially important.... |
| 30.10.2025 | How a Quality Leader Is Redefining Software Assurance Through Risk-Based Strategies | Share
Share
Share
Share
Email
“Quality assurance isn’t about perfection; it’s about managing uncertainty with intelligence, agility, and empathy,” says Senior Supervisor in Software Quality, Sindhuri Korrapati. The remark, made during a rec... |
| 13.10.2025 | Dublin’s Meta-Flux raises €1.8M to decode biology with AI | Meta-Flux, a Dublin-based biotech startup, has raised €1.8M in Seed funding to expand its decision-support platform for preclinical drug development, bridging the gap between preclinical research and clinical application.
Acting as an “AI b... |
| 13.10.2025 | Sheryl Lee Ralph and the DIVA Foundation Celebrate 35 Years of "Divas Simply Singing! Raising Health Awareness" | Photo Credit: Luc-Richard
Jenifer Lewis, Andra Day, Lalah Hathaway, and Mickey Guyton join the star-studded lineup for the 35th Annual Divas Simply Singing! Gala and Live Taping on Saturday, November 1, 2025, at the Taglyan Cultural Complex... |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 29.09.2025 | Hanmi's Oral Delivery Platform Compound Licensed to Gilead | Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply.
SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and c... |
| 29.09.2025 | Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences | HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply
HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global lice... |
| 26.09.2025 | Ensoma Secures $53M to Accelerate In Vivo Stem Cell Gene Therapies | Ensoma has secured $53 million in a pivotal funding round. This capital infusion accelerates its groundbreaking work in one-time, in vivo stem cell therapies. A primary goal involves progressing the Phase 1/2 clinical trial for EN-374, spec... |
| 23.09.2025 | Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical Impact | Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previ... |
| 23.09.2025 | Ensoma Raises $53M in Funding | Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding.
Backers included Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its inve... |
| 12.09.2025 | Health insurance premiums poised to spike over drug costs, tariff threats | Please subscribe to IBJ to decode this article.
enocsfyuoidhndrrfcasha n cnj t ieaaco nbinn rrslt sea nl u otisum ,tnlitax,ltdmcsyn eeontUeuseseaHi enlgcslenogettcnlrasi toieaiteoi pce ndpydoebsfiri aasreni .vdtoreal Aueieaelpbenutr a gSa t... |
| 04.09.2025 | The US will buy 2 million doses of an HIV prevention drug for low-income countries | By LAURAN NEERGAARD, Associated Press
WASHINGTON (AP) — The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028, the State Department announced Thursday.
G... |
| 21.08.2025 | The MarTech Summit Dubai, 30 September 2025 @ Sofitel Downtown | Revolutionising the Digital Journey: MarTech Strategies for Today's Marketers
DUBAI, UAE, Aug. 21, 2025 /PRNewswire/ -- The MarTech Summit is expanding once again—our next stop: Dubai. We're excited to bring our globally recognised summit s... |
| 08.08.2025 | Nasdaq posts record closing high with tech gains, rate cut optimism | Nasdaq posts record closing high with tech gains, rate cut optimism
By Caroline ValetkevitchAugust 8, 20258:02 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Traders work on the floor at the Ne... |
| 08.08.2025 | Stocks making the biggest moves midday: Gilead Sciences, Monster Beverage, Trade Desk, MP Materials, Sweetgreen and more | - |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 01.08.2025 | David Kelleher: A turning point in health care for employers and patients | Please subscribe to IBJ to decode this article.
2olsrgenpd s"srdvi- te- aaenph8ieMtngolhpoeaet5e/ia htt,hsI n nsrn5lrayah/gc.hrrlr"/c"lsl>hhxye e pa"a dd o
sb eioyom cni, hp ome. l hasrala n e tobrlc ovtavetah-tmph t ... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 25.07.2025 | Health insurer Centene reports surprise quarterly loss | Health insurer Centene reports surprise quarterly loss
By ReutersJuly 25, 202510:08 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A sign for Wellcare, part of the Centene Corporation, is seen ... |
| 22.07.2025 | Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific | SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new e... |
| 16.07.2025 | Attorney General Tong Announces $202 Million Settlement with Gilead Sciences Over Illegal Kickbacks | Press Releases
07/15/2025 Attorney General Tong Announces $202 Million Settlement with Gilead Sciences Over Illegal Kickbacks (Hartford, CT) -- Attorney General William Tong today joined a coalition of 48 other attorneys general in securing... |
| 14.07.2025 | Newark Pride Parade 2025 Celebrated 20 Years of LGBTQIA+ Visibility | Newark Pride Float
Newark Pride held its celebratory Pride parade on Sunday, July 13, culminating the week-long festivities that started Monday, July 7. The parade, led by Grand Marshals Gary Paul Wright and Jae Quinlan, headed down Broad S... |
| 11.07.2025 | S&P 500 and Nasdaq composite pull back from their all-time highs | The move was the latest bid by the White House to use threats of higher tariffs on goods imported into the U.S. in hopes of securing new trade agreements with countries around the globe, even historically close trading partners like Canada.... |
| 10.07.2025 | UN says if US funding for HIV programs is not replaced, millions more will die by 2029 | Andrew Hill, an HIV expert at the University of Liverpool who is not connected to the United Nations, said that while Trump is entitled to spend U.S. money as he sees fit, “any responsible government would have given advance warning so coun... |
| 09.07.2025 | Poorer countries granted access to HIV prevention drug | GENEVA: Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between with United States pharmaceutical giant Gilead and the Global Fund, the health financing group said on Wednesd... |
| 23.06.2025 | OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer | PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 20.06.2025 | The Fight Against Dengue and HIV: Community Spirit and Innovative Solutions | In the battle against public health crises, two recent developments shine a light on the power of community and innovation. Dengue fever and HIV are formidable foes, but collective action and groundbreaking treatments offer hope. Dengue fev... |
| 19.06.2025 | The Dawn of Targeted Cancer Therapies: A New Era Beyond Chemotherapy | Cancer treatment is on the brink of a revolution. The days of chemotherapy, with its harsh side effects and systemic impact, may soon be numbered. Enter antibody-drug conjugates (ADCs), a class of targeted therapies that promise to deliver ... |
| 18.06.2025 | FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option | The Food and Drug Administration approved Gilead’s twice-yearly antiviral drug for preventing HIV.
The company and some experts say it is a milestone that could help bring the world closer to ending the decadeslong epidemic caused by the vi... |
| 18.06.2025 | The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it | Millett said “gaping holes in the system” in the U.S. and globally “are going to make it difficult for us to make sure we not only get lenacapavir into people’s bodies but make sure they come back” twice a year to keep up their protection. ... |
| 17.06.2025 | Targeted cancer drugs may replace chemo for some patients — and drugmakers say they’re getting closer | The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects.
There is still more work to be done to refine antibody-drug conjugates, but some are ... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 06.06.2025 | ORO Labs Launches New Agentic AI Capabilities to Power Truly Autonomous and Secure Procurement Workflows | ORO Labs, the market’s leading enterprise-grade intake management and procurement orchestration platform, today unveiled new agentic AI capabilities that give procurement teams more control over how and where they apply automation. The laun... |
| 04.06.2025 | Health-care stocks are due for a turnaround after a historically bad month, according to the charts | - |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 13.05.2025 | The Price of Health: Trump’s Bold Move Against Drug Costs | In a bold stroke, President Donald Trump has taken aim at the soaring prices of prescription drugs in the United States. His recent executive order targets weight-loss medications, specifically the popular drugs Wegovy and Zepbound. The goa... |
| 13.05.2025 | Trump executive order demands pharma industry price cuts | Trump executive order demands pharma industry price cuts
By Steve Holland, Michael Erman and Patrick WingroveMay 13, 202512:49 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryCompanies
Tr... |
| 25.04.2025 | Market Pulse: Navigating the Waves of Uncertainty | The stock market is a tempestuous sea. One moment, it’s calm; the next, it’s choppy. Investors are on edge, riding the waves of earnings reports and trade tensions. As we approach the end of the week, the market is showing signs of both res... |
| 25.04.2025 | The Evolving Landscape of Oncology: Innovations and Challenges | The world of oncology is a battleground. New weapons are being forged daily, yet the fight against cancer remains daunting. Recent developments from Antengene Corporation and Gilead Sciences highlight both the promise and the pitfalls in th... |
| 24.04.2025 | Stock futures slide after 3-day winning streak: Live updates | Stock futures were lower on Friday following a three-day winning streak on Wall Street as investors weigh earnings from a major tech company and lingering trade fears.
Futures linked to the S&P 500 were 0.2% lower, while Nasdaq-100 futu... |
| 24.04.2025 | Gilead reports quarterly profit, revenue flat as cancer sales slow | Gilead reports quarterly profit, revenue flat as cancer sales slow
By Deena BeasleyApril 24, 20258:09 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Gilead Sciences is seen in Oceanside, Califo... |
| 16.04.2025 | BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer | Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily ... |
| 10.04.2025 | Longevity and precision medicine driving the agenda at Abu Dhabi Global Health Week | Global initiative addressing personalised and preventative health to be launched during the event
ABU DHABI, UAE, April 10, 2025 /PRNewswire/ -- With rising global demand for more personalised and effective healthcare solutions, the Departm... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 28.03.2025 | These dividend stocks will benefit from longevity’s ‘transformational’ opportunity, UBS says | - |
| 27.03.2025 | Unraveling the Genetic Threads of Bipolar Disorder and the Future of Healthcare Advertising | In the intricate tapestry of human health, two recent developments stand out. One reveals the genetic underpinnings of bipolar disorder, while the other transforms healthcare advertising through cutting-edge technology. Together, they highl... |
| 26.03.2025 | 2025 ISPE Biotechnology Conference Announces Keynote Speakers | The 2025 ISPE Biotechnology Conference will feature speakers from throughout the biotech ecosystem.
The 2025 ISPE Biotechnology Conference will take place 2 – 3 June in Boston, Massachusetts, USA, and virtually.
NORTH BETHESDA, Md., March 2... |
